

PCT

WORLD INTELLEC
In

INTERNATIONAL APPLICATION PUBLISHED

WO 9603427A1

(51) International Patent Classification 6 :

C07K 5/08, A61K 51/08

A1

(43) International Publication Date: 8 February 1996 (08.02.96)

(21) International Application Number: PCT/CA95/00249

(22) International Filing Date: 28 April 1995 (28.04.95)

(30) Priority Data:
08/279,155 22 July 1994 (22.07.94) US(60) Parent Application or Grant
(63) Related by Continuation
US 08/279,155 (CIP)
Filed on 22 July 1994 (22.07.94)

(71) Applicant (for all designated States except US): RESOLUTION PHARMACEUTICALS INC. [CA/CA]; 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): POLLAK, Alfred [CA/CA]; Apartment 1400, 135 Marlee Avenue, Toronto, Ontario M6B 4C6 (CA). GOODBODY, Anne [CA/CA]; 31 Hiawatha Road, Toronto, Ontario M4L 2X7 (CA).

(74) Agent: WOODLEY, John, H.; Sim & McBurney, Suite 701, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).


Published

With international search report.

(54) Title: PEPTIDE DERIVED RADIONUCLIDE CHELATORS

(57) Abstract

For use in imaging sites of diagnostic interest within the body, the present invention provides radionuclide chelators of formula (I), wherein X is a linear or branched, saturated or unsaturated C₁₋₄alkyl chain that is optionally interrupted by one or two heteroatoms selected from N, O and S; and is optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, C₁₋₄alkyl, aryl and C(O)Z; Y is H or a substituent defined by X; X and Y may together form a 5- to 8-membered saturated or unsaturated heterocyclic ring optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, oxo, C₁₋₄alkyl, aryl and C(O)Z; R¹ through R⁴ are selected independently from H; carboxyl; C₁₋₄alkyl; C₁₋₄alkyl substituted with a group selected from hydroxyl, amino, sulfhydryl, halogen, carboxyl, C₁₋₄alkoxycarbonyl and aminocarbonyl; an alpha carbon side chain of a D- or L-amino acid other than proline; and C(O)Z; R⁵ and R⁶ are selected independently from H; carboxyl; amino; C₁₋₄alkyl; C₁₋₄alkyl substituted by hydroxyl, carboxyl or amino; and C(O)Z; R⁷ is selected from H and a sulfur protecting group; and Z is selected from hydroxyl, C₁₋₄alkoxy and a targeting molecule.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PEPTIDE DERIVED RADIONUCLIDE CHELATORS

Field of the Invention

5 This invention is in the field of diagnostic imaging, and relates to chemical chelators useful in the radiolabeling of agents that target tissues of diagnostic interest.

Background to the Invention

10 The art of diagnostic imaging exploits contrasting agents that in binding or localizing site selectively within the body, help to resolve the image of diagnostic interest. ^{67}Ga salts, for example, have an affinity for tumours and infected tissue and, with the aid of scanning tomography, can reveal afflicted body regions to the physician. Other contrasting agents include the
15 metal radionuclides such as $^{99\text{m}}\text{Tc}$ and $^{186/188}\text{Re}$, and these have been used to label targeting molecules, such as proteins, peptides and antibodies that localize at desired regions of the human body.

As targeting agents, proteins and other macromolecules can offer the tissue specificity required for diagnostic accuracy; yet labeling of these agents with
20 metal radionuclides is made difficult by their physical structure. Particularly, protein and peptide targeting agents present numerous sites at which radionuclide binding can occur, resulting in a product that is labeled heterogeneously. Also, and despite their possibly large size, proteins rarely present the structural configuration most appropriate for high affinity
25 radionuclide binding, i.e. a region incorporating four or more donor atoms that form five-membered rings. As a result, radionuclides are bound typically at the more abundant low-affinity sites, forming unstable complexes.

To deal with the problem of low affinity binding, Paik et al (Nucl Med Biol
30 1985, 12:3) proposed a method whereby labeling of antibodies is performed in the presence of excess DPTA (diaminetrimethylenepentaacetic acid), to mask the low affinity binding sites. While the problem of low affinity binding is alleviated by this method, actual binding of the radionuclide, in this case technetium, was consequently also very low. The direct labeling of proteins
35 having a high proportion of cysteine residues also has been demonstrated


5

10

15

20

25



wherein

X is a linear or branched, saturated or unsaturated C₁₋₄alkyl chain that is optionally interrupted by one or two heteroatoms selected from N, O and S; and is optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, C₁₋₄alkyl, aryl and C(O)Z;

Y is H or a substituent defined by X;

X and Y may together form a 5- to 8-membered saturated or unsaturated heterocyclic ring optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, oxo, C₁₋₄alkyl, aryl and C(O)Z;

R¹ through R⁴ are selected independently from H; carboxyl; C₁₋₄alkyl; C₁₋₄alkyl substituted with a group selected from hydroxyl, amino, sulfhydryl, halogen, carboxyl, C₁₋₄alkoxycarbonyl and aminocarbonyl; an alpha carbon side chain of a D- or L-amino acid other than proline; and C(O)Z;


R⁵ and R⁶ are selected independently from H; carboxyl; amino; C₁₋₄alkyl; C₁₋₄alkyl substituted by hydroxyl, carboxyl or amino; and C(O)Z;

R⁷ is selected from H and a sulfur protecting group; and

Z is selected from hydroxyl, C₁₋₄alkoxy and a targeting molecule.

According to another aspect of the invention, the chelators of the invention are provided in a form having a metal radionuclide complexed therewith having the general formula:

(II)



wherein

X is a linear or branched, saturated or unsaturated C₁₋₄alkyl chain that is optionally interrupted by one or two heteroatoms selected from N, O

and S; and is optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, C₁₋₄alkyl, aryl and C(O)Z;

Y is H or a substituent defined by X;

5 X and Y may together form a 5- to 8-membered saturated or unsaturated heterocyclic ring optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, oxo, C₁₋₄alkyl, aryl and C(O)Z;

10 R¹ through R⁴ are selected independently from H; carboxyl; C₁₋₄alkyl; C₁₋₄alkyl substituted with a group selected from hydroxyl, amino, sulfhydryl, halogen, carboxyl, C₁₋₄alkoxycarbonyl and aminocarbonyl; an alpha carbon side chain of a D- or L-amino acid other than proline; and C(O)Z;

R⁵ and R⁶ are selected independently from H; carboxyl; amino; C₁₋₄alkyl; C₁₋₄alkyl substituted by hydroxyl, carboxyl or amino; and C(O)Z;

15 Z is selected from hydroxyl, C₁₋₄alkoxy and a targeting molecule; and

M is a metal radionuclide or an oxide or nitride thereof.

20 In another aspect of the invention, there is provided a conjugate in which the chelator is provided in a form coupled to a diagnostically useful targeting molecule, and optionally in combination with a complexed metal radionuclide, for imaging use.

25 In another aspect of the invention, there is provided a method of imaging sites of diagnostic interest in which a conjugate of the invention is first administered as a radionuclide complex to a patient; and then the location of the radionuclide is detected using imaging means.

Brief Description of the Drawings

30 Figure 1 is an HPLC analysis of conjugate N,N-dimethylGly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH labeled with ^{99m}Tc.

Detailed Description of the Invention

The invention provides metal radionuclide chelators that when coupled to a targeting molecule are useful for delivering a radionuclide to a body site of

therapeutic or diagnostic interest. As illustrated in the above formula, the chelators are peptidic compounds that present an N₃S configuration in which the radionuclide is complexed.

Terms defining the variables R¹ - R⁷, X, Y and Z as used hereinabove have the following meanings:

"alkyl" refers to a straight or branched C₁₋₄ chain;

"aryl" refers to aromatic and heteroaromatic rings;

"halogen" refers to F, Cl and Br;

"sulfur protecting group" refers to a chemical group that inhibits oxidation of a thiol group, which includes those that are cleaved upon chelation of the metal. Suitable sulfur protecting groups include known alkyl, aryl, acyl, alkanoyl, aryloyl, mercaptoacyl and organothio groups.

In preferred embodiments of the invention, the chelators conform to the above formula in which:

R¹ through R⁴ are selected independently from H; and a hydroxy-substituted C₁₋₄alkyl group such as hydroxymethyl and 1-hydroxyethyl;

R⁵ and R⁶ are selected independently from H and C₁₋₄alkyl, and are preferably both H;

R⁷ is a hydrogen atom or a sulfur protecting group and is most preferably acetamidomethyl;

X is a C₁₋₄alkyl chain, preferably methyl or ethyl; or is a C₁₋₄alkyl chain substituted with an aryl group, preferably to form a benzyl group;

Y is H or a substituent defined by X; and is preferably methyl, ethyl or benzyl and most preferably is the same as X;

Z is OH, C₁₋₄alkoxy or a targeting molecule, and is preferably a peptide targeting molecule.

Specific chelators of the invention include:

N,N-dimethylGly-Ser-Cys(Acm)-OH;

N,N-dimethylGly-Thr-Cys(Acm)-OH;

N,N-diethylGly-Ser-Cys(Acm)-OH;

N,N-dibenzylGly-Ser-Cys(Acm)-OH; and

Sarcosine-Ser-Cys(Acm)-OH.

In the case where the substituents represented by X and Y together with the adjacent nitrogen atom form a hetero ring, such a ring may be a 5- to 8-membered, saturated ring, for example pyrrolidine, piperidine, 1-azacycloheptane and 1-azacyclooctane. Unsaturated rings formed by X and Y include pyrrole and 4H-pyridine while it is understood that the coordinating nitrogen of the ring is necessarily trivalent and cannot form a double bond to an adjacent atom. The heterocycle formed by X and Y may also incorporate one or two additional heteroatoms selected from N, O and S. Rings having additional heteroatoms include but are not limited to 1-imidazole, pyrazole, piperazine, morpholine and thiomorpholine. The ring formed by X and Y may also be substituted with one or more and preferably less than three groups selected from halogen, hydroxyl, carboxyl, oxo, C₁₋₄alkyl and aryl, for example to form 4-oxo-1-piperidine, 4-oxo-1-pyrrolidine and 4-hydroxy-1-piperidine.

For diagnostic imaging purposes, the chelator pre se may be used in a form complexed with a metal radionuclide. Suitable radionuclides include ^{99m}Tc, ⁶⁴Cu, ⁶⁷Cu, ⁹⁷Ru, ¹⁰⁵Rh, ¹⁰⁹Pd, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁹⁸Au, ¹⁹⁹Au, ²⁰³Pb, ²¹²Pb and ²¹²Bi in their various oxides or nitrides. Preferred metal radionuclides are technetium (^{99m}Tc) and rhenium (^{186,188}Re) in their oxide forms such as ReO³⁺, ReO₂⁺, ^{99m}TcO₂⁺ and most preferably ^{99m}TcO₃⁺. Desirably and according to a preferred aspect of the invention, the chelator is coupled to a targeting molecule represented by Z in the above formula, to form a conjugate that serves to deliver a chelated radionuclide to a desired location in a mammal. Examples of targeting molecules suitable for coupling to the chelator include, but are not limited to, steroids, proteins, peptides, antibodies, nucleotides and saccharides. Preferred targeting molecules include proteins and peptides, particularly those capable of binding with specificity to cell surface receptors characteristic of a particular pathology. For instance, disease states associated with over-expression of particular protein receptors can be imaged by labeling that protein or a receptor binding fragment thereof coupled to a chelator of invention. Most preferably targeting molecules are peptides capable of specifically binding to target sites and have three or more amino acid residues. Targeting peptides useful

to image certain medical conditions and tissues are noted below:

for atherosclerotic plaque:

YRALVDTLK

RALVDTLK

RALVDTLK FVTQAEGAK

YAKFRETLEDTRDRMY

AKFRETLEDTRDRMY

AALDLNAVANKIADFEL

YAALDLNAVANKIADFEL

YRALVDTLK FVTEQAKGA

RALVDTLK FVTEQAKGA

YRALVDTEFKVKQEAGAK

RALVDTEFKVKQEAGAK

YRALVDTLK FVTQAEGAK

10

for infections and atherosclerotic plaque:

VG VAPGVGVAPGVGVAPG

formyl.Nleu.LF.Nleu.YK

VPGVGVPGVGVPGVGVPGVG

formylMIFL

formylMLFK

formylMLFI

formylMFIL

formylMFLI

15

formylMLIF

formylMILF

formylTKPR

VG VAPG

formylMLF

YIGSR

CH₂CO.YIGSRC

20

for thrombus:

NDGDFEEIPEEYLQ

NDGDFEEIPEEY(SO₃Na)LQ

GPRG

for platelets:

25

D-Phe.PRPGGGGNGDFEEIPEEYL

RRRRRRRRRGDV

PLYKKIIKKLLES

RGD

RGDS

for amyloid plaque (Alzheimer's disease):

30

EKPLQNFTLSFR

For connection to the chelator, a targeting molecule may comprise a "spacer" that serves to create a physical separation between the chelator and the targeting molecule. A spacer may be an alkyl chain that is

derivatized for coupling to the chelator. In the case where the targeting molecule is a peptide, the spacer may suitably be one or more amino acid residues. Preferably, peptidic targeting molecules incorporate spacers of from 1 to 5 amino acids such having chemically inert α -carbon side chains, such as glycine or β -alanine residues.

A targeting molecule may be coupled to a chelator of the invention at various sites including R^1 to R^6 , X, Y and Z as well as a ring formed by X and Y. Coupling may be achieved by reacting a group present on the targeting molecule that is reactive with a substituent on the chelator to form a linkage. For example, peptide targeting molecules having a free amino group, such as an N-terminus or an ϵ -amino-lysine group may be reacted with a carboxyl group on the chelator to form an amide linkage. Alternatively, the C-terminus of the peptide targeting molecule may be reacted with an amino substituent on the chelator. In a preferred embodiment, targeting molecules are coupled to chelators of formula (I) at substituent Z by an amide linkage such as a peptide bond. For example, the N-terminus amino group of a peptide targeting molecule is reacted with a carboxyl group at Z. Targeting molecules other than peptides may be coupled to chelators of the invention in a similar manner provided that a group suitable for coupling to the chelator is present. In the instance that a suitable group is not present, the targeting molecule may be chemically derivatized to present such a group. When more than one reactive group is present on the chelator or targeting molecule, it is desirable to block all but the particular group for coupling with an appropriate blocking agent in order to achieve a single conjugate species. For example, free carboxyl groups may be protected by forming esters such as a t-butyl ester which can be removed with TFA. Free amino groups may be protected with a blocking group such as Fmoc which may be subsequently removed with piperidine.

In a particular embodiment of the invention, imaging *in vivo* sites of focal inflammation is accomplished using a conjugate in which the targeting molecule is a chemotactic peptide comprising the amino acid sequence Thr-Lys-Pro-Pro-Lys (TKPPR). It has been found that this peptide binds

particularly well to leukocytes receptors. Targeting peptides can be spaced from the chelator by additional amino acid residues, preferably glycine, provided the peptide retains its localizing activity. In a particular embodiment, the peptide TKPPR is coupled to substituent Z of chelators according to formula (I) by a Gly residue.

Peptide-based targeting molecules can be made, either per se or as a conjugate with a chelator, using various established techniques. Because it is amenable to solid phase synthesis, employing alternating Fmoc protection and deprotection is the preferred method of making short peptides. Recombinant DNA technology is preferred for producing proteins and long fragments thereof. In a particular embodiment, peptide-chelator conjugates are prepared by solid-phase peptide synthesis methods, which involve the stepwise addition of amino acid residues to a growing peptide chain that is linked to an insoluble (solid) support or matrix, such as polystyrene. The C-terminal residue of the targeting peptide is first anchored to a commercially available support with its amino group protected with an N-protecting agent such as a fluorenylmethoxycarbonyl (Fmoc) group. Typically, the support is obtained with the C-terminal residue preloaded in protected form. The amino protecting group is removed with suitable deprotecting agents such as piperidine and the next amino acid residue (in N-protected form) is added with a coupling agent such as dicyclocarbodiimide (DCC). Upon formation of a peptide bond, the reagents are washed from the support. Once the targeting peptide chain is synthesized, the first residue of the chelator ie. S-acetamidomethyl protected cysteine is added to the N-terminus. The final residue of the chelator is a derivatized amino acid residue that conforms to the formula (X)(Y)N-C(R¹)(R²)-CO- wherein X, Y, R¹ and R² have the meaning previously defined. The final residue, for example dimethyl-glycine, diethyl-glycine, dibenzyl-glycine or sarcosine, may be commercially obtained or synthesized. The completed conjugate is cleaved from the support with a suitable reagent such as trifluoroacetic acid (TFA).

It will be appreciated that all substituents R¹ through R⁴ according to the invention are side chains of naturally occurring or derivatized amino acids

including D-amino acids and are commercially available and compatible with solid phase synthesis techniques. Derivatized amino acid residues that are not commercially available may be incorporated in chelators of the invention by synthesizing them according to established organic chemistry techniques and inserting at the appropriate stage of solid phase peptide synthesis previously described. Similarly when substituents R⁵ and R⁶ are other than H, a derivatized cysteine amino acid residue is utilized in the peptide synthesis. For example, the commercially available residue penecillamine is incorporated when R⁵ and R⁶ are both methyl.

Various substituents at X and Y may be introduced in chelators of the invention by incorporating as the final residue of solid phase synthesis a derivatized amino acid according to the formula (X)(Y)N-C(R¹)(R²)-C(O)-OH wherein X, Y, R¹ and R² have the meaning previously described. Amino acids having N-terminal amino substituents according to X and Y may be synthesized according to established organic chemistry procedures and techniques. For example, when X and Y are both dibenzyl substituents the corresponding dibenzylglycine residue may be synthesized by reacting commercially available reagents bromoacetic acid and dibenzylamine in a suitable solvent such as dichloromethane and then heating. Other amines may be employed in the reaction in place of dibenzylamine such as diisopropylamine to give the corresponding diisopropylglycine. Similarly cyclic amines such as piperidine and morpholine in place of dibenzylamine will give the corresponding piperidyl-glycine and morpholinyl-glycine residues.

In a most preferred embodiment of the invention a peptide-chelator conjugate is prepared on a solid support and has the structure of formula (I) wherein the targeting molecule is a peptide having a sequence Gly-Thr-Lys-Pro-Pro-Arg-OH; R¹, R², R³, R⁵ and R⁶ are H; R⁴ is hydroxymethyl or 1-hydroxyethyl and R⁷ is acetamidomethyl.

Incorporation of the selected radionuclide within the chelator can be achieved by various established methods. For example the following general

procedure may be used. A chelator solution is formed initially by dissolving the chelator in aqueous alcohol eg. ethanol-water 1:1. Oxygen is removed for example by degassing with N₂, then sodium hydroxide is added to remove the thiol protecting group. The solution is again purged of oxygen and heated on a water bath to hydrolyze the thiol protecting group, and the solution is then neutralized with an organic acid such as acetic acid (pH 6.0-6.5). In the labeling step, sodium pertechnetate is added to a chelator solution with an amount of stannous chloride sufficient to reduce the technetium. The solution is mixed and left to react at room temperature and then heated on a water bath. In an alternative method, labeling can be accomplished with the chelator solution adjusted to pH 8. At this higher pH, pertechnetate may be replaced with a solution containing technetium complexed with labile ligands suitable for ligand exchange reactions with the desired chelator. Suitable ligands include tartarate, citrate and heptagluconate. Stannous chloride may be replaced with sodium dithionite as the reducing agent if the chelating solution is alternatively adjusted to a still higher pH of 12-13 for the labeling step. The chelators of the present invention can be coupled to a targeting molecule prior to labeling with the radionuclide, a process referred to as the "bifunctional chelate" method. An alternative approach is the "prelabeled ligand" method in which the chelator is first labeled with a radionuclide and is then coupled to the targeting molecule.

The labeled chelator may be separated from contaminants ^{99m}TcO₄⁻ and colloidal ^{99m}TcO₂ chromatographically, e.g., with a C-18 Sep Pak column activated with ethanol followed by dilute HCl. Eluting with dilute HCl separates the ^{99m}TcO₄⁻, and eluting with EtOH-saline 1:1 brings off the chelator while colloidal ^{99m}TcO₂ remains on the column.

When coupled to a targeting molecule and labeled with a diagnostically useful metal, chelators of the present invention can be used to detect pathological conditions by techniques common in the art of diagnostic imaging. A chelator-targeting molecule conjugate labeled with a radionuclide metal such as technetium may be administered to a mammal

intralymphatically, intraperitoneally and preferably intravenously in a pharmaceutically acceptable solution such as saline or blood plasma medium. The amount of labeled conjugate administered is dependent upon the toxicity profile of the chosen targeting molecule as well as the profile of the metal and is typically in the range of about 0.01 to 100 and preferably 10 to 50mCi per 70Kg host. Localization of the metal *in vivo* is tracked by standard scintigraphic techniques at an appropriate time subsequent to its administration. The time at which an image may be obtained will depend upon the profile of the targeting molecule, for example most peptides will localize rapidly allowing for an image to be obtained within 3 hours and often within 1 hour. In a particular embodiment, chelators of the invention coupled to a peptide targeting molecule GTKPPR in a saline solution are administered by intravenous injection to image sites of focal inflammation.

The following examples are presented to illustrate certain embodiments of the present invention.

Example 1 - Preparation of Peptide-Chelator Conjugates

N,N-dimethylGly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg
N,N-dimethylGly-Thr-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg and
Sarcosine-Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg

The title conjugates were prepared as a single peptide chain by solid phase peptide synthesis using Fmoc chemistry on an Fmoc-arginine preloaded 2 - methoxy-4-alkoxybenzyl alcohol resin (Sasrin Resin, Bachem Biosciences Inc., Philadelphia) with an Applied Biosystems 433A peptide synthesizer (Foster City, CA). Derivatized amino acid residues S-acetamidomethyl-cysteine (Bachem), N,N-dimethylglycine (Sigma Chemical Company, St. Louis, MO), and sarcosine were incorporated at the appropriate step of chain elongation.

Upon addition of the final residue N,N-dimethylGly or Sarcosine, the peptide-resin was dried under vacuum overnight and cleavage of the peptide from the resin was achieved by mixing a cooled solution of 9.5mL trifluoroacetic

acid (TFA), 0.5mL water, 0.5mL thioanisole and 0.25mL 2-ethanedithiol (1mL per 100mg of peptide-resin) with the peptide-resin for 1.5 to 2 hours at room temperature. The resin was removed by filtration and washed with 1-3mL of TFA to obtain 6-8mL of a clear yellow liquid. This liquid was slowly dropped into 30-35mL of cold tert-butyl ether in a 50mL conical polypropylene centrifuge tube forming a white precipitate. The precipitate was centrifuged at 7000rpm, 0°C for 5 minutes (Sorvall RT6000, Dupont), decanted and washed two more times with tert-butyl ether. Following drying under vacuum the precipitate was dissolved in water. The solution was frozen in acetone-dry ice and lyophilized overnight. The resulting white powder was dissolved in water, filtered through a 0.45µm syringe filter (Gelman Acrodisc 3 CR PTFE), and purified by reversed-phase HPLC (Beckman System Gold) with a C18 column (Waters RCM 25 x 10) using 1% TFA in water as buffer A and 1% TFA in acetonitrile as buffer B. The column was equilibrated with 100:0 buffer A:buffer B and eluted with a linear gradient in 25 minutes at 1mL/min to 50% buffer B. Fractions were reanalysed on the HPLC and pooled according to matching profiles. The pure fractions were frozen in acetone-dry ice and lyophilized 12 hours to give a white powder.

Example 2 - Preparation of Peptide-Chelator Conjugate

N,N-dibenzylGly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg

N,N-diethylGly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg

The title conjugate was prepared as a single peptide chain by solid phase peptide synthesis using Fmoc chemistry on an Fmoc-arginine preloaded 2-methoxy-4-alkoxybenzyl alcohol resin (Sasrin Resin, Bachem Biosciences Inc., Philadelphia) with an Applied Biosystems 433A peptide synthesizer (Foster City, CA). Derivatized amino acid residues S-acetamidomethyl-cysteine (Bachem) N,N-diethylglycine and N,N-dibenzylglycine were incorporated at the appropriate step of chain elongation.

The derivatized amino acid residue N,N-dibenzylglycine was synthesized by the following procedure:

In a flask equipped with magnetic stir, bromoacetic acid (5.00g, 35.99mmol) was dissolved in CH_2Cl_2 , cooled to 0°C and dibenzylamine (8.31mL, 43.79mmol) was added. The reaction mixture was stirred at 0°C for 1h and allowed to warm to room temperature and then heated to between $30\text{--}40^\circ\text{C}$ for 12 hours. The mixture solution was cooled to room temperature and CH_2Cl_2 was evaporated under reduced pressure, then washed with hot ethanol and dried under vacuum giving a white solid residue (71.2% yield).

The derivatized amino acid residue N,N-diethylglycine was synthesized by the following procedure:

In a flask, chloroacetic acid (5.00g, 52.91mmol) was added to diethylamine (35mL) and stirred for 12 hours at room temperature then heated at reflux for 72 hours. The reaction mixture was cooled to room temperature and neutralized with HCl and concentrated to reduced volume. Ethylacetate and EtOH were then added and the resulting white precipitate was filtered and dried under vacuum to give 1.74g (25% yield) of the product.

Example 3- Labeling of Peptide-Chelator Conjugates

N,N-dimethylGly-Ser-Cys(Acm)-GTKPPR

N,N-dimethylGly-Thr-Cys(Acm)-GTKPPR

N,N-diethylGly-Ser-Cys(Acm)-GTKPPR

N,N-dibenzylGly-Ser-Cys(Acm)-GTKPPR and

Sarcosine-Ser-Cys(Acm)-GTKPPR

The conjugates of examples 1 and 2 were reconstituted ($200\mu\text{L}$, 1mg/mL saline) and then injected into 3mL vacutainers with $100\mu\text{L}$ pertechnetate (10mCi) and $100\mu\text{L}$ stannous gluconate ($50\mu\text{g}$ stannous chloride and 1 mg sodium gluconate). The tubes were placed in boiling water bath for 12 minutes and then filtered through a Whatman PVDF syringe filter to collect the labeled conjugate solutions which were further diluted with saline to prepare injectable solutions (2M bq/mL). The conjugates were isolated by HPLC (Beckman) from a ($20\mu\text{L}$) sample (before dilution) to determine the

labeling yield by measuring radioactivity.

	conjugate	labelling yield
5	N,N-dimethylGly-Ser-Cys(Acm)-GTKPPR	> 94%
	N,N-dimethylGly-Thr-Cys(Acm)-GTKPPR	> 94%
	N,N-diethylGly-Ser-Cys(Acm)-GTKPPR	85.4%
	N,N-dibenzylGly-Ser-Cys(Acm)-GTKPPR	98.9%
10	Sarcosine-Ser-Cys(Acm)-GTKPPR	90.3%

Each conjugate except Sarcosine-Ser-Cys(Acm)-GTKPPR gave a single peak and greater than 85% labeling yield. 24 hours after labeling, N,N-dimethylGly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg was reanalyzed on HPLC and observed to have no degradation or radiolysis products.

Example 4- *In vivo* Imaging and Biodistribution of Conjugates

Rat inflammation studies were performed as follows. 2 male Wistar rats (Charles River, 200-250g) were injected intramuscularly with (25mg) zymosan, a yeast cell wall suspension, into their left hindlegs 24 hours before imaging. Focal inflammation in the leg was visually detectable after 1 day. 1mg (ca. 0.7 μ Mol) of the chelator-peptide conjugate was dissolved in 50 μ L of dimethylsulfoxide and added to an ethanol-water mixture (1:1, 200 μ L). An aliquot of Tc-99m tartarate (ca. 400 MBq) was added and transchelation allowed to proceed for 20 min. at 100°C. The Tc-99m labeled conjugate was purified by elution through a Sep Pak cartridge and then diluted with saline to prepare an injectable formulation (200 μ L) containing about 100 μ Ci (3.7 MBq) of activity.

The rats were anaesthetized with somnitol (40 to 50 mg/kg), and the labeled conjugate solution (200 μ L) was injected intravenously via the tail vein. Serial whole-body scintigrams were acquired at 30 minutes. The rats were then killed with anaesthesia overdose and samples of organs, urine, blood,

5 inflamed muscle (left leg) and non-inflamed muscle (right leg) and inflammatory exudate (fluid) were weighed and counted in either a well-type gamma counter or in a gamma dose calibrator depending upon the organ. The dose calculations were made based on the assumption that the blood volume constituted 8% of body weight. The results of the conjugates represented in the table below are averages for two rats and are corrected for the residual dose in the tail.


10 Both conjugates gave excellent scintigraphic images in comparison to other known inflammation imaging agents such as Ga-67, ^{99m}Tc -IgG, ^{111}In -WBC and ^{99m}Tc -Nanocoll which is indicated by the high target to background ratios (inflamed:uninflamed muscle) observed. The conjugates imaged much more rapidly than the known agents and exhibited superior biodistribution. Also, non-target organs such as liver and GI tract showed low accumulation.

15

Imaging Agent	Inflam: Uninfl	Fluid: Blood	Urine (% dose)	Liver (% dose)	GI Tract (% dose)
N,N-dimethylGly-Ser- Cys(Acm)-GTKPPR-OH	5.3	1.9	63.5	2.4	2.8
N,N-dimethylGly-Thr- Cys(Acm)-GTKPPR-OH	4.6	1.6	68.5	2.4	2.5
N,N-dibenzylGly-Ser- Cys(Acm)-GTKPPR-OH	3.7	0.4	55.1	2.3	7.5
⁶⁷ Ga	2.5	0.1	5.5	26.5	8.4
^{99m} Tc-IgG	2.8	0.03	1.2	17.6	0.7
¹¹¹ In-WBC	1.5	0.1	0.2	36.9	3.6
^{99m} Tc-Nanocoll	3.3	0.2	0.8	66.7	2.1

WE CLAIM:

1. A compound of the general formula:



wherein

X is a linear or branched, saturated or unsaturated C₁₋₄alkyl chain that is optionally interrupted by one or two heteroatoms selected from N, O and S; and is optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, C₁₋₄alkyl, aryl and C(O)Z;

Y is H or a substituent defined by X;

X and Y may together form a 5- to 8-membered saturated or unsaturated heterocyclic ring optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, oxo, C₁₋₄alkyl, aryl and C(O)Z;

R¹ through R⁴ are selected independently from H; carboxyl; C₁₋₄alkyl; C₁₋₄alkyl substituted with a group selected from hydroxyl, amino, sulfhydryl, halogen, carboxyl, C₁₋₄alkoxycarbonyl and aminocarbonyl; an alpha carbon side chain of a D- or L-amino acid other than proline; and C(O)Z;

R⁵ and R⁶ are selected independently from H; carboxyl; amino; C₁₋₄alkyl; C₁₋₄alkyl substituted by hydroxyl, carboxyl or amino; and C(O)Z;


R⁷ is selected from H and a sulfur protecting group; and

Z is selected from hydroxyl, C₁₋₄alkoxy and a targeting molecule.

2. A compound according to claim 1, wherein R^1 , R^2 , R^4 , R^5 and R^6 are hydrogen.
3. A compound according to claim 1, wherein X and Y are independently selected from C_{1-4} alkyl and aryl substituted C_{1-4} alkyl.
4. A compound according to claim 1, wherein R^3 is selected from hydroxymethyl and 1-hydroxyethyl.
5. A compound according to claim 1, wherein Y is independently a substituent defined by X.
6. A compound according to claim 5, wherein X and Y are the same group selected from methyl, ethyl and benzyl.
7. A compound according to claim 5, wherein R^3 is selected from hydroxymethyl and 1-hydroxyethyl.
8. A compound according to claim 5, wherein R^1 , R^2 , R^4 , R^5 and R^6 are hydrogen.
9. A compound according to claim 1, wherein Z is a targeting molecule.
10. A compound according to claim 9, wherein the targeting molecule is a peptide.
11. A compound according to claim 10, wherein the peptide comprises 3 or more amino acid residues.
12. A compound according to claim 11, wherein the peptide comprises the sequence TKPPR.

13. A compound according to claim 12, wherein the peptide comprises the sequence Gly-Thr-Lys-Pro-Pro-Arg-OH.
14. A compound according to any preceding claim, in a form complexed with a metal radionuclide or an oxide or nitride thereof.
15. A compound according to claim 14, wherein said metal radionuclide is selected from ^{99m}Tc , ^{64}Cu , ^{67}Cu , ^{87}Ru , ^{105}Rh , ^{108}Pd , ^{186}Re , ^{188}Re , ^{198}Au , ^{199}Au , ^{203}Pb , ^{212}Pb and ^{212}Bi .
16. A compound according to claim 14, wherein said metal radionuclide is selected from ^{99m}Tc , ^{186}Re and ^{188}Re .
17. A compound according to claim 14, wherein said metal radionuclide is ^{99m}Tc .
18. A compound of the general formula:

(II)



wherein

X is a linear or branched, saturated or unsaturated C_{1-4} alkyl chain that is optionally interrupted by one or two heteroatoms selected from N, O and S; and is optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, C_{1-4} alkyl, aryl and $\text{C}(\text{O})\text{Z}$;

Y is H or a substituent defined by X;

X and Y may together form a 5- to 8-membered saturated or unsaturated heterocyclic ring optionally substituted by at least

one group selected from halogen, hydroxyl, amino, carboxyl, oxo, C₁₋₄alkyl, aryl and C(O)Z;

R¹ through R⁴ are selected independently from H; carboxyl; C₁₋₄alkyl; C₁₋₄alkyl substituted with a group selected from hydroxyl, amino, sulfhydryl, halogen, carboxyl, C₁₋₄alkoxycarbonyl and aminocarbonyl; an alpha carbon side chain of a D- or L-amino acid other than proline; and C(O)Z;

R⁵ and R⁶ are selected independently from H; carboxyl; amino; C₁₋₄alkyl; C₁₋₄alkyl substituted by hydroxyl, carboxyl or amino; and C(O)Z;

Z is selected from hydroxyl, C₁₋₄alkoxy and a targeting molecule; and M is a metal radionuclide or an oxide or nitride thereof.

19. A compound according to claim 18, wherein M is selected from ^{99m}Tc, ⁶⁴Cu, ⁶⁷Cu, ⁹⁷Ru, ¹⁰⁵Rh, ¹⁰⁹Pd, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁸⁸Au, ¹⁹⁹Au, ²⁰³Pb, ²¹²Pb and ²¹²Bi and oxides or nitrides thereof.
20. A compound according to claim 18, wherein M is selected from ^{99m}Tc, ¹⁸⁶Re and ¹⁸⁸Re and oxides or nitrides thereof.
21. A compound according to claim 18, wherein M is ^{99m}Tc or oxides or nitrides thereof.
22. A method of detecting the localization of a targeting molecule within a mammal comprising the step of administering a diagnostically effective amount of a compound according to claim 14, wherein Z is the targeting molecule.
23. The method according to claim 22, wherein said metal radionuclide is ^{99m}Tc.

24. A method of imaging a site of focal inflammation within a mammal comprising the step of administering a diagnostically effective amount of a compound according to claim 10, in a form complexed with a metal radionuclide or an oxide or nitride thereof.
25. The method according to claim 24, wherein said metal radionuclide is ^{99m}Tc .
26. A method of imaging a site of focal inflammation within a mammal comprising the step of administering an effective amount of a compound according to claim 12, in a form complexed with a metal radionuclide or an oxide or nitride thereof.
27. The method according to claim 26, wherein said metal radionuclide is ^{99m}Tc .
28. A compound according to claim 1, selected from
N,N-dimethylGly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH;
N,N-dimethyl-Gly-Thr-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH;
N,N-diethylGly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH; and
N,N-dibenzylGly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH.
29. The compound according to claim 28, in a form complexed with a metal radionuclide or an oxide or nitride thereof.
30. The compound according to claim 29, wherein said metal radionuclide is ^{99m}Tc .




FIGURE 1

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/CA 95/00249A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K5/08 A61K51/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 12819 (RHOMED INC.) 8 July 1993 see the whole document ---	1-30
X	EP,A,0 250 013 (MALLINCKRODT) 23 December 1987 see the whole document ---	18-21
X	JOURNAL OF NUCLEAR MEDICINE., vol.35, no.5SUP, June 1994, NEW YORK US pages 44P - 45P A POLLAK ET AL. 'Imaging inflammation with novel peptide Technetium-99m chelators linked to a chemotactic peptide' see the whole document --- -/--	1-30

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *B* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

27 July 1995

Date of mailing of the international search report

06.10.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Masturzo, P

INTERNATIONAL SEARCH REPORT

Application No
PCT/CA 95/00249

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>JOURNAL OF NUCLEAR MEDICINE., vol.35, no.2, February 1994, NEW YORK US pages 282 - 288 L C KNIGHT ET AL. 'Thrombus imaging with Technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets' see the whole document -----</p>	1-30

INTERNATIONAL SEARCH REPORT

I,  al application No.

PCT/CA95/00249

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 24 and 26
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 24 and 26 refer to a diagnostic method performed on the human body, the search was carried out and was based on the alleged effects of the compositions.
2. ☒ Claims Nos.: 1-11, 13-27, 29-30
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Please see attached sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Reason of the limitation of the search (Art. 6 PCT)

The general formula of claim 1 is so vague that it might include all the tripeptides having an optionally S-protected cysteine in C-terminal position.

The use of obscure formulations (e. g. "targeting molecule" in claim 1, which can include all the molecules whose presence is recognized by the organism) and the paucity of examples (only chelating moieties of the formula [mono- or dialkyl(aryl)]-Glycyl-(Seryl or Threonyl)-(S-protected) cysteine are provided) would oblige the Search Division to perform a search on an extremely broad domain. So broad searches are considered to be impossible for economical reasons and therefore the Search Division restricted the subject searched to the real examples occurring in the present application.

INTERNATIONAL SEARCH REPORT

Indication on patent family members

International : Application No

PCT/CA 95/00249

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9312819	08-07-93	US-A- 5346687	13-09-94
		AU-B- 3427293	28-07-93
		EP-A- 0629133	21-12-94

EP-A-0250013	23-12-87	AU-B- 611854	27-06-91
		AU-A- 7360587	01-12-88
		CA-A- 1316296	13-04-93
		JP-A- 62289596	16-12-87
		US-A- 4849511	18-07-89
		US-A- 5187264	16-02-93
